{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:17Z","timestamp":1793083997007,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81501888"],"award-info":[{"award-number":["81501888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10787-019-00624-2","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T12:19:39Z","timestamp":1566994779000},"page":"1123-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["IL-1\u03b2, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"624_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320:1360\u20131372. \nhttps:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"624_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/art.30207","volume":"63","author":"K Bendtzen","year":"2011","unstructured":"Bendtzen K (2011) Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 63:867\u2013870. \nhttps:\/\/doi.org\/10.1002\/art.30207","journal-title":"Arthritis Rheum"},{"key":"624_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/eji.201344184","volume":"44","author":"G Benedetti","year":"2014","unstructured":"Benedetti G, Miossec P (2014) Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol 44:339\u2013347. \nhttps:\/\/doi.org\/10.1002\/eji.201344184","journal-title":"Eur J Immunol"},{"key":"624_CR4","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3537\u20133545. \nhttps:\/\/doi.org\/10.1172\/JCI36389","journal-title":"J Clin Invest"},{"key":"624_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/art.20711","volume":"52","author":"MH Buch","year":"2005","unstructured":"Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P (2005) C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 52:42\u201348. \nhttps:\/\/doi.org\/10.1002\/art.20711","journal-title":"Arthritis Rheum"},{"key":"624_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE (2017) Novel treatment strategies in rheumatoid arthritis. Lancet 389:2338\u20132348. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(17)31491-5","journal-title":"Lancet"},{"key":"624_CR7","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/ar3431","volume":"13","author":"DY Chen","year":"2011","unstructured":"Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2011) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 13:R126. \nhttps:\/\/doi.org\/10.1186\/ar3431","journal-title":"Arthritis Res Ther"},{"key":"624_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/s0140-6736(88)90185-7","volume":"2","author":"JA Eastgate","year":"1988","unstructured":"Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW (1988) Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2:706\u2013709. \nhttps:\/\/doi.org\/10.1016\/s0140-6736(88)90185-7","journal-title":"Lancet"},{"key":"624_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1177\/0961203314543915","volume":"23","author":"AM Eudy","year":"2014","unstructured":"Eudy AM, Vines AI, Dooley MA, Cooper GS, Parks CG (2014) Elevated C-reactive protein and self-reported disease activity in systemic lupus erythematosus. Lupus 23:1460\u20131467. \nhttps:\/\/doi.org\/10.1177\/0961203314543915","journal-title":"Lupus"},{"key":"624_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/tcrm.2007.3.1.99","volume":"3","author":"B Haraoui","year":"2007","unstructured":"Haraoui B, Bykerk V (2007) Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 3:99\u2013105. \nhttps:\/\/doi.org\/10.2147\/tcrm.2007.3.1.99","journal-title":"Ther Clin Risk Manag"},{"key":"624_CR11","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3899\/jrheum.090132","volume":"36","author":"SY Kawashiri","year":"2009","unstructured":"Kawashiri SY et al (2009) Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 36:2397\u20132402. \nhttps:\/\/doi.org\/10.3899\/jrheum.090132","journal-title":"J Rheumatol"},{"key":"624_CR12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kes094","volume":"51","author":"K Kayakabe","year":"2012","unstructured":"Kayakabe K et al (2012) Interleukin-1beta measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford) 51:1639\u20131643. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kes094","journal-title":"Rheumatology (Oxford)"},{"key":"624_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10067-011-1737-y","volume":"30","author":"SA Metawi","year":"2011","unstructured":"Metawi SA, Abbas D, Kamal MM, Ibrahim MK (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30:1201\u20131207. \nhttps:\/\/doi.org\/10.1007\/s10067-011-1737-y","journal-title":"Clin Rheumatol"},{"key":"624_CR14","doi-asserted-by":"publisher","first-page":"698192","DOI":"10.1155\/2014\/698192","volume":"2014","author":"X Niu","year":"2014","unstructured":"Niu X, Chen G (2014) Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis. J Immunol Res. 2014:698192. \nhttps:\/\/doi.org\/10.1155\/2014\/698192","journal-title":"J Immunol Res."},{"key":"624_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1303006","volume":"369","author":"JR O'Dell","year":"2013","unstructured":"O'Dell JR et al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369:307\u2013318. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1303006","journal-title":"N Engl J Med"},{"key":"624_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF02274836","volume":"10","author":"M Rooney","year":"1990","unstructured":"Rooney M, Symons JA, Duff GW (1990) Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 10:217\u2013219","journal-title":"Rheumatol Int"},{"key":"624_CR17","first-page":"73","volume":"53","author":"A Rosu","year":"2012","unstructured":"Rosu A, Margaritescu C, Stepan A, Musetescu A, Ene M (2012) IL-17 patterns in synovium, serum and synovial fluid from treatment-naive, early rheumatoid arthritis patients. Rom J Morphol Embryol 53:73\u201380","journal-title":"Rom J Morphol Embryol"},{"key":"624_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/14397595.2017.1317384","volume":"28","author":"R Shi","year":"2018","unstructured":"Shi R, Chen M, Litifu B (2018) Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol 28:126\u2013132. \nhttps:\/\/doi.org\/10.1080\/14397595.2017.1317384","journal-title":"Mod Rheumatol"},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5114\/ceji.2018.80045","volume":"43","author":"D Sikorska","year":"2018","unstructured":"Sikorska D, Rutkowski R, Luczak J, Samborski W, Witowski J (2018) No effect of anti-TNF-alpha treatment on serum IL-17 in patients with rheumatoid arthritis. Cent Eur J Immunol 43:270\u2013275. \nhttps:\/\/doi.org\/10.5114\/ceji.2018.80045","journal-title":"Cent Eur J Immunol"},{"key":"624_CR20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"624_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","volume":"75","author":"RF van Vollenhoven","year":"2016","unstructured":"van Vollenhoven RF et al (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75:52\u201358. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2014-205726","journal-title":"Ann Rheum Dis"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-019-00624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-019-00624-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-019-00624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T19:50:10Z","timestamp":1598471410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-019-00624-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s10787-019-00624-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}